PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

44,990 stories, page 634 of 750

Advanced search
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06583486: A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06349460: Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06281119: Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06031441: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05950464: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05934487: PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05806437: Patient Blood Management in the Approach to Prosthetic Surgery [PBM(L4178)]

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05698199: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05354505: Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05110989: A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT04566432: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT04555577: Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT02603081: Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT00378924: Cardiology Biobank Registry

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Can't Japan Cultivate Top-Tier Biotech Companies?

36KrOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

GC Wellbeing clinches Korea rights to Raziel fat-shot as US phase 3 nears - CHOSUNBIZ

ChosunbizOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

GC Green Cross Wellbeing Introduces Fat-Dissolving Injectable Ahead of U.S. Phase 3 Clinical Trials

아시아경제Original source
🇪🇸Industryrovi.esTier 1 · Company source

Informe Country by Country Público_Grupo Norbel FY25

Laboratorios RoviOriginal source
🇪🇸Industryrovi.esTier 1 · Company source

Otro información relevante

Laboratorios RoviOriginal source
🌍discoverynews.google.comTier 2 · Trade media

FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med

MedCity NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Bill Aims to Extend Cybersecurity Review of Made-in-China Medical Devices

mb.ntd.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

The Manila TimesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

BridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasia

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

BridgeBio's achondroplasia drug posts NEJM Phase 3 data

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical Desiccant Sachets Market Growth to Accelerate by 2035 Amid Biologic Drug Expansion and Stricter Moisture Control Mandates - News and Statistics

IndexBoxOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial

AstraZenecaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial

AstraZeneca USOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Top supplements Americans use are shifting from multivitamins to targeted health fixes

MSNOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Viridian's thyroid eye disease drug wins FDA nod, squaring off with Amgen's Tepezza

FirstWord PharmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Is Viking Therapeutics Stock a No-Brainer Buy Below $35?

AOL.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

The overlooked reason why new drugs take so long—and the $10 trillion fix

Fox BusinessOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Nearly 1 Million Heart And Kidney Medication Bottles Recalled In Major FDA Alert

NewswavOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

“Medicine Security Is National Security”: PSGH Demands 70% Local Drug Production

Modern GhanaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Teva Pharmaceutical's Innovative Shift Continues With Ecopipam Addition (NYSE:TEVA)

Seeking AlphaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA busts Rs 52-lakh expired food racket; FIR filed against Amazon warehouse officials

Mid-dayOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Psilocybin Could Become the First FDA-Approved Psychedelic Therapy Within Months — Here Is What Patients Need to Know

Medical DailyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA approves first single-dose generic treatment for influenza

Gulf Coast MediaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

10 Best Biotech Stocks to Buy According to Analysts

Insider MonkeyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

5 Best Biotech Stocks to Buy According to Analysts

Insider MonkeyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to earnings forward of Vytrus Biotech SA – BME:VYT

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Russian Strike Damages Kyiv Pharmaceutical Plant During Attack

Caspian PostOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Hackensack Meridian Health Joins Phase 3 Trial of Pfizer’s Investigational C difficile Vaccine

Contagion LiveOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Russian strike damaged Darnytsia pharmaceutical plant in Kyiv, no casualties

mezha.netOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Approves BESREMi Pen for Self-Administration in Polycythemia Vera

Oncology Nursing NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Generic Enzalutamide Tablets Granted Tentative FDA Approval for Prostate Cancer

OncLiveOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Gas Chromatography Systems Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Quality Mandates

IndexBoxOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Leadership’s “Blind Spots” Lead to a Surge in Medical Device and Drug Recalls

brownstone.orgOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Conducts Surprise Inspection At Parbhani Girls Hostel Kitchen, Checks Food Safety

Free Press JournalOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAW

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Phase 3 TRIDENT Trial Misses Survival End Point in Glioblastoma

Targeted OncologyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Russians hit pharmaceutical manufacturer Darnytsia in Kyiv

YahooOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?

The Motley FoolOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Phase 3 RECONNECT Trial: ZYN002 Fails to Meet Primary Endpoint in Fragile X Syndrome Population

Vera HealthOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?

The Globe and MailOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to book forward of Hangzhou Alltest Biotech Co., Ltd. Class A – SSE:688606

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Is Viking Therapeutics stock a no-brainer buy below $35?

MSNOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to earnings forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390

TradingViewOriginal source